These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2461594)

  • 1. Interferon in the treatment of ovarian cancer.
    Welander CE
    Semin Oncol; 1988 Oct; 15(5 Suppl 5):26-9. PubMed ID: 2461594
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of alpha and gamma interferons and cytostatics on ovarian cancer in the subrenal capsule assay.
    Grönroos M; Mäenpää J; Söderström KO; Kangas L; Leppänen M; Cantell K
    Med Biol; 1983; 61(5):275-9. PubMed ID: 6200736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer.
    Bezwoda WR; Seymour L; Dansey R
    Cancer; 1989 Sep; 64(5):1029-33. PubMed ID: 2758381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor effect of interferons with chemotherapeutic agents].
    Kimoto Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):293-301. PubMed ID: 3080964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal administration of interferon beta in ovarian cancer patients.
    Rambaldi A; Introna M; Colotta F; Landolfo S; Colombo N; Mangioni C; Mantovani A
    Cancer; 1985 Jul; 56(2):294-301. PubMed ID: 2408731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating interferon in rabbits after simultaneous intramuscular administration of human alpha and gamma interferons.
    Cantell K; Fiers W; Hirvonen S; Pyhälä L
    J Interferon Res; 1984; 4(2):291-3. PubMed ID: 6431022
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer.
    Mäenpää J; Kivinen S; Räisänen I; Sipilä P; Väyrynen M; Gröhn P
    Ann Chir Gynaecol Suppl; 1994; 208():25-7. PubMed ID: 8092765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma].
    Marth C; Mull R; Gastl G; Herold M; Steiner E; Daxenbichler G; Hetzel H; Flener R; Huber C; Dapunt O
    Geburtshilfe Frauenheilkd; 1989 Nov; 49(11):987-91. PubMed ID: 2511058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs.
    Welander CE
    Cancer; 1987 Feb; 59(3 Suppl):617-9. PubMed ID: 3802026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor effects of natural human tumor necrosis factor and mouse interferon beta and gamma.
    Itano S; Fuchimoto S; Orita K
    Hiroshima J Med Sci; 1987 Jun; 36(2):219-25. PubMed ID: 2443470
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacokinetics of human interferons].
    Furue H; Kobayashi H; Komuro T; Kako M; Mugitani H; Fuse K; Kaise R; Nagai K; Takahashi T; Hirota F
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):935-42. PubMed ID: 6721508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of routes of administration of interferon in cancer: a review and a proposal.
    Bocci V
    Cancer Drug Deliv; 1984; 1(4):337-51. PubMed ID: 6085757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocavitary beta-interferon in neoplastic effusions.
    Cherchi PL; Campiglio A; Rubattu A; Desole A; Andria G; Ambrosini A
    Eur J Gynaecol Oncol; 1990; 11(6):477-9. PubMed ID: 2086232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis and management of refractory malignant ascites].
    Saâda E; Follana P; Peyrade F; Mari V; François E
    Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfa interferon: combinations with other antineoplastic modalities.
    Bonnem EM
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):48-60. PubMed ID: 3296212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
    D'Acquisto R; Markman M; Hakes T; Rubin S; Hoskins W; Lewis JL
    J Clin Oncol; 1988 Apr; 6(4):689-95. PubMed ID: 3128649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is hyperthermic intraoperative peritoneal chemotherapy and systemic chemotherapy as effective as standard intraperitoneal chemotherapy: time for a prospective trial?
    Edwards RP
    Gynecol Oncol; 2011 Aug; 122(2):207-8. PubMed ID: 21763889
    [No Abstract]   [Full Text] [Related]  

  • 19. [Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease].
    Cherchi PL; Dessole S; Esposito F; Ambrosini G; El Qandil FZ; Ambrosini A
    J Gynecol Obstet Biol Reprod (Paris); 1996; 25(1):101-2. PubMed ID: 8901311
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraperitoneal alpha interferon for ovarian cancer: a case report.
    Carney-Gersten P; Moore MD; Giuffre M
    Oncol Nurs Forum; 1990; 17(3):403-7. PubMed ID: 2342974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.